Pancreatic Cancer Research

ResearcherUniversity of ChicagoActive in the last 2 years

Ralph R. Weichselbaum

ORCID-verified (high confidence)As of 10 November 2026

Matched on ORCID iD 0000-0002-5643-8939; OpenAlex author ID A5054855052; NIH RePORTER profile ID 1888723.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
1
Labs led
1
Collaborators
3
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 2 papers, 1 grant

Papers 3

  1. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  2. Engineered probiotic Bifidobacterium for tumor-targeted pancreatic cancer therapy. Co-author DOI 10.1126/sciadv.adz1388↗
  3. STING (or SRC) Like an ICB: Priming the Immune Response in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-19-1700↗

Grants 1

  1. Genetically-engineered Bacteria Overcome Therapy Resistance R01CA292860↗

Closest collaborators

The 3 strongest of 3 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

  1. Mark Mimee · 1 shared paper, 1 shared grant, 2026
  2. Jaehyun Lee · 1 shared paper, 2026
  3. Stanley I. Gutiontov · 1 shared paper, 2019

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.